Opthea Strengthens Leadership Team Ahead of Upcoming Trials
Parisa Zamiri, MD, PhD, and Tom Reilly have been appointed as Chief Medical Officer (CMO) and Chief Financial Officer (CFO) respectively. Additionally, Anand Sundaram has been appointed as Vice President of Marketing. These key hires signify Opthea Limited's commitment to advancing its efforts in developing innovative therapies targeted at progressive retinal diseases.
Overview of New Executive Team
Opthea Limited, a biopharmaceutical company focused on treating retinal diseases like wet age-related macular degeneration (wet AMD), has welcomed new leaders to its team. These appointments come at a crucial time as the company prepares for the topline data readouts for sozinibercept in Phase 3 clinical trials COAST and ShORe in 2025.
Chief Medical Officer: Parisa Zamiri, MD, PhD
Dr. Parisa Zamiri joins Opthea as the Chief Medical Officer, bringing a wealth of experience in ocular therapeutics. Reporting directly to CEO Frederic Guerard, she will lead clinical development and regulatory affairs. Dr. Zamiri's track record includes previous roles at Complement Therapeutics and Novartis Pharmaceuticals, making her an invaluable asset in steering the company’s clinical strategies.
Chief Financial Officer: Tom Reilly
Taking the role of Chief Financial Officer, Tom Reilly has a distinguished background in finance within the life sciences sector. His previous leadership positions at Amarin Corporation and Novartis have provided him with critical insights into strategic financial planning and operations. Mr. Reilly's expertise will ensure that Opthea remains financially robust as it pursues its growth objectives.
Marketing Leadership: Anand Sundaram
As the new Vice President of Marketing, Anand Sundaram will be instrumental in shaping Opthea’s marketing strategies. His experience spans over ten years in commercial roles within major pharmaceutical companies, where he successfully led strategies for numerous product launches. His work at Astellas and Novartis uniquely positions him to enhance Opthea’s market presence as it introduces novel therapies.
Corporate Vision and Future Outlook
With competitive candidates in leadership roles, Opthea is well-positioned not only to advance the development of its lead candidate, sozinibercept, but also to expand its overall commercial readiness. Frederic Guerard emphasized that these strategic appointments augment the existing expertise within the company, fortifying its commitment towards achieving regulatory approvals and enhancing therapeutic options for patients.
The Importance of Sozinibercept Trials
Sozinibercept is currently undergoing evaluation in two pivotal Phase 3 clinical trials (NCT04757636 for COAST and NCT04757610 for ShORe). These trials aim to demonstrate the efficacy of sozinibercept in providing significant vision improvements when used alongside standard anti-VEGF-A therapy. The upcoming data readouts expected in 2025 will be crucial in demonstrating the potential advantages of sozinibercept over existing treatments.
About Opthea Limited
Opthea Limited is dedicated to addressing urgent medical needs in ophthalmology through cutting-edge biopharmaceutical solutions. The company strives to develop effective treatments for retinal diseases that significantly impact vision and quality of life.
Frequently Asked Questions
What role has Parisa Zamiri taken at Opthea?
Parisa Zamiri has been appointed as the Chief Medical Officer, overseeing clinical development and regulatory affairs.
Who is the new Chief Financial Officer of Opthea?
Tom Reilly is the newly appointed Chief Financial Officer, with over 25 years of experience in finance within the life sciences industry.
What is the focus of Opthea's clinical trials?
Opthea's clinical trials are focused on sozinibercept, with goals to assess its efficacy in treating wet age-related macular degeneration.
How does Anand Sundaram contribute to Opthea?
Anand Sundaram, as Vice President of Marketing, will enhance marketing strategies and oversee the launch of new therapies.
What is the significance of the Phase 3 trial data readouts?
The Phase 3 trial data readouts are crucial for potential regulatory submissions and could significantly influence the treatment landscape for retinal diseases.
